Clinical course during the 3-month study period and results of repeat imaging
| . | Rivaroxaban (n = 73) . | Standard anticoagulation (n = 41) . |
|---|---|---|
| Clinical course, n (%) | ||
| During the 3-mo treatment period | ||
| Headache lasting >2 wk* | 6 (8.2) | 2 (4.9) |
| Epileptic seizure | 1 (1.4) | 0 |
| At 3 mo | ||
| Mortality | 0 | 0 |
| Persisting focal neurological deficits† | 5 (6.8) | 3 (7.3) |
| Persisting decreased vision | 4 (5.5) | 1 (2.4) |
| Inability to walk/move as before the CVT | 1 (1.4)‡ | 0 |
| Requirement of more help with ADL than before the CVT | 4 (5.5)§ | 3 (7.3) |
| Results of repeat imaging at 3 mo, n (%) | ||
| New nonhemorrhagic infarct or intracerebral hemorrhage | 0 | 0 |
| Change in thrombotic burden as compared with index event | ||
| Normalized | 18 (25) | 6 (15) |
| Improved | 39 (53) | 24 (59) |
| No relevant change | 5 (6.8) | 4 (9.8) |
| Asymptomatic deterioration | 0 | 1 (2.4) |
| Uncertain|| | 11 (15) | 5 (12) |
| . | Rivaroxaban (n = 73) . | Standard anticoagulation (n = 41) . |
|---|---|---|
| Clinical course, n (%) | ||
| During the 3-mo treatment period | ||
| Headache lasting >2 wk* | 6 (8.2) | 2 (4.9) |
| Epileptic seizure | 1 (1.4) | 0 |
| At 3 mo | ||
| Mortality | 0 | 0 |
| Persisting focal neurological deficits† | 5 (6.8) | 3 (7.3) |
| Persisting decreased vision | 4 (5.5) | 1 (2.4) |
| Inability to walk/move as before the CVT | 1 (1.4)‡ | 0 |
| Requirement of more help with ADL than before the CVT | 4 (5.5)§ | 3 (7.3) |
| Results of repeat imaging at 3 mo, n (%) | ||
| New nonhemorrhagic infarct or intracerebral hemorrhage | 0 | 0 |
| Change in thrombotic burden as compared with index event | ||
| Normalized | 18 (25) | 6 (15) |
| Improved | 39 (53) | 24 (59) |
| No relevant change | 5 (6.8) | 4 (9.8) |
| Asymptomatic deterioration | 0 | 1 (2.4) |
| Uncertain|| | 11 (15) | 5 (12) |